Altimmune's intranasal COVID-19 vaccine shows sterilizing potential

By The Science Advisory Board staff writers

May 10, 2021 -- Preclinical data for Altimmune's intranasal AdCOVID vaccine candidate show the drug has sterilizing immunity potential after a single dose.

Sterilizing immunity is considered critical for blocking transmission of the virus, the company said. Data came from a preclinical mouse study that showed a single dose of AdCOVID blocked virus uptake in vaccinated mice compared to unvaccinated counterparts.

Altimmune plans to release phase I data from an AdCOVID clinical trial in June. The trial is evaluating three dose levels of the vaccine, according to the firm.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.